Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, according to a new study.

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's ...

Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how ...

Eli Lilly (LLY) reported better-than-expected earnings for the second quarter on Thursday. But disappointing results of its much-awaited oral GLP-1 pill sent the stock down 13% in early trading. The ...

In the realm of innovative health solutions, the HonXi SMGT-GLP-1 Nano Microneedle Patch stands out as a revolutionary approach to managing weight and controlling blood sugar levels. As the prevalence ...

The trial randomized 559 participants across the U.S., China, India, Japan and Mexico in 1:1:1:1 ratio to receive either 3 mg, 12 mg or 36 mg orforglipron or placebo.

For the primary endpoint, orforglipron 36 mg, taken once per day without food and water restrictions, lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo using ...